Deticene - General Information

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)


Pharmacology of Deticene

After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.


Deticene for patients

This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the way
cancer cells grow, Take your doses on a regular scheduled time and DO
NOT take this medicine more often than directed by your health care
provider. Finish the full course prescribed by your health care provider.
DO NOT stop taking this medicine unless diredted to do so by your health
care provider. While taking this medicine, you make get infection more
easily. Call your doctor if you get a fever, chills, or sore throat.
Drink plenty of water with this medicine.


Deticene Interactions

No Information Provided.


Deticene Contraindications

DTIC-Dome is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.


Additional information about Deticene

Deticene Indication: For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents
Mechanism Of Action: Possibly blocking the formation of inosinic acid.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Dacarbazine
Synonyms: Dacarbazino [Inn-Spanish]; Dacarbazinum [Inn-Latin]; DIC; DTIC; Dtic-Dome; ICDMT; Imidazole Carboxamide; ICDT; DTIE; Biocarbazine R
Drug Category: Antineoplastic Agents; Antineoplastic Agents, Alkylating
Drug Type: Small Molecule; Approved

Other Brand Names containing Dacarbazine: Deticene;
Absorption: Erratic, slow and incomplete
Toxicity (Overdose): LD50=350mg/kg (orally in mice)
Protein Binding: Less than 5%
Biotransformation: Hepatic
Half Life: 5 hours
Dosage Forms of Deticene: Powder, for solution Intravenous
Chemical IUPAC Name: (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
Chemical Formula: C6H10N6O
Dacarbazine on Wikipedia:
Organisms Affected: Humans and other mammals